霍奇金淋巴瘤新的预后标志及治疗
摘要
1霍奇金淋巴瘤的生物学预后标志过去经典霍奇金淋巴瘤（HL）患者的预后参数包括肿块大小、患者年龄、病灶数量、血沉或国际预后积分（IPS）等临床指标。IPS不能将病人准确区分为良好、中间及不良三群,因为0～3个危险因素的患者5年FFP几乎相同,而有4个或4个以上危险因素的患者其预后也相同。
出处
《癌症进展》
2011年第6期667-672,共6页
Oncology Progress
参考文献34
-
1Moccia M A,Donaldson J,Chhanabhai M,et al.The International Prognostic Factor Project Score (IPS) in advanced stage hodgkin lymphoma has limited utility in patients treated in the modern era[J].Blood,2009,114:Abstr 1554.
-
2Steidl C,Lee T,Shah SP,et al.Tumor-associated macrophages and survival in classic Hodgkin's lymphoma[J].N Engl J Med,2010,362:875-885.
-
3Rassidakis G Z,Medeiros L J,Viviani S,et al.CD20 Expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's diease:associations with presenting features and clinical outcome[J].J Clin Oncol,2002,20:1278-1287.
-
4Visco C,Nadali G,Vassilakopoulos T P,et al.Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis[J].Eur J Haematol,2006,77:387-394.
-
5Rassidakis G Z,Medeiros L J,Vassilakopoulos T P,et al.BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin diease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens[J].Blood,2002,100:3935-3941.
-
6Montalban C,Garcia J F,Abraira V,et al.Influence of biologic markers on the outcome of Hodgkin's lymphoma:a study by the Spanish Hodgkin's lymphoma Study Group[J].J Clin Oncol,2004,22:1664-1673.
-
7Alvaro T,Lejeune M,Salvado M T,et al.Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells[J].Clin Cancer Res,2005,11:1467-1473.
-
8Kelley T W,Pohlman B,Elson P,et al.The ratio of FOXP3 + regulatory T cells to granzyme B + cytotoxic T/NK cells predicts prognosis in classical Hodgkin's lymphoma and is independent of bcl-2 and MAL expression[J].Am J Clin Pathol,2007,128:958-965.
-
9Bartlett N L,Younes A,Carabasi M H,et al.A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 + hematologic malignancies[J].Blood,2008,111:1848-1854.
-
10Forero-Torres A,Leonard J P,Younes A,et al.A Phase Ⅱ study of SGN-30 (anti-CD30 mAb) in Hodgkin's lymphoma or systemic anaplastic large cell lymphoma[J].Br J Haematol,2009,146:171-179.
-
1纪泛扑.肝细胞癌中高迁移率蛋白组A1表达的检测:一个潜在的预后标志[J].世界核心医学期刊文摘（胃肠病学分册）,2006,0(3):10-11.
-
2向锦,张梅芳,符珈,云径平.乳腺癌组织β-catenin表达及与预后关系的分析[J].中华肿瘤防治杂志,2012,19(10):753-756. 被引量：7
-
3王琳,李世拥,安萍,蔡惠芸.Claudin-1和Claudin-4在结直肠癌组织中的表达及临床意义[J].中华胃肠外科杂志,2012,15(10):1073-1076. 被引量：4
-
4万文丽(综述),田磊(综述),克晓燕(审校).霍奇金淋巴瘤的研究进展[J].白血病．淋巴瘤,2014,23(5):308-311. 被引量：8
-
5中国慢性淋巴细胞白血病的诊断与治疗指南（2011年版）[J].中华血液学杂志,2011,32(7):498-501. 被引量：56
-
6刘奇,田兴松,丛明华,杨朝花,朱见,周文红,李凯,吴国君.乳腺癌组织EG-1和Her-2表达及其与预后关系的探讨[J].中华肿瘤防治杂志,2010,17(19):1547-1550. 被引量：6
-
7李建勇,邱录贵.中国慢性淋巴细胞白血病诊断与治疗专家共识[J].中华血液学杂志,2010,31(2):141-144. 被引量：24
-
8赵国徽,王家宏,贾志勇,赵艳飞.Survivin与结直肠癌关系的研究进展[J].包头医学院学报,2011,27(6):132-134. 被引量：2
-
9杜俊瑶.卵巢癌首次化疗后CA125是否一过性上升[J].国外医学（妇产科学分册）,2006,33(4):300-300.
-
10孟迪,冯晓燕,进淑娟,戴振华,韩小伟,郝晓鹏,张贺秋,黄焰.CD44v6、MUC1及VEGF在三阴性乳腺癌组织中的表达及其临床意义[J].肿瘤学杂志,2014,20(2):91-96. 被引量：12
